Organogenesis Holdings (ORGO) Non-Current Assets (2015 - 2026)
Organogenesis Holdings (ORGO) recorded quarterly Non-Current Assets of $251.5 million in Q1 2026, up 6.32% quarter-over-quarter from $236.5 million in Q4 2025, and up 26.23% on a YoY basis from $199.2 million in Q1 2025.
Organogenesis Holdings (ORGO) Non-Current Assets (2015 - 2026) Analysis & Trends
Organogenesis Holdings' Non-Current Assets history runs 12 years deep, the most recent figure standing at $251.5 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 26.23% year-over-year to $251.5 million; the TTM figure through Mar 2026 stood at $899.0 million (up 8.59% YoY), while the FY2025 annual figure was $236.5 million, up 11.61% from the prior year.
- Non-Current Assets was $251.5 million for Q1 2026 at Organogenesis Holdings, up from $236.5 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $251.5 million in Q1 2026 to a low of $199.2 million in Q1 2025.
- Historically, Non-Current Assets has averaged $223.0 million across 5 years, with a median of $226.7 million in 2022.
- The sharpest annual moves came in 2022 and 2025: Non-Current Assets surged 63.07% in 2022, then dropped 13.87% in 2025.
- A 5-year view of Non-Current Assets shows it stood at $226.8 million in 2022, then climbed by 3.63% to $235.0 million in 2023, then fell by 9.8% to $211.9 million in 2024, then increased by 11.61% to $236.5 million in 2025, then grew by 6.32% to $251.5 million in 2026.
- The last three Non-Current Assets figures came in at $251.5 million (Q1 2026), $236.5 million (Q4 2025), and $210.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 26.33 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 8.68 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 3.84 Bn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 2.47 Bn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 9.64 Bn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 2.90 Bn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 1.40 Bn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 1.22 Bn |
| 10 | Organogenesis Holdings | 304.80 Mn | 212.70 Mn | 11.46 Mn | 251.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 251.49 Mn |
| Dec 31, 2025 | 236.54 Mn |
| Sep 30, 2025 | 210.08 Mn |
| Jun 30, 2025 | 200.91 Mn |
| Mar 31, 2025 | 199.23 Mn |
| Dec 31, 2024 | 211.95 Mn |
| Sep 30, 2024 | 207.79 Mn |
| Jun 30, 2024 | 208.97 Mn |
| Mar 31, 2024 | 231.31 Mn |
| Dec 31, 2023 | 234.98 Mn |
| Sep 30, 2023 | 237.07 Mn |
| Jun 30, 2023 | 233.88 Mn |
| Mar 31, 2023 | 229.29 Mn |
| Dec 31, 2022 | 226.75 Mn |
| Sep 30, 2022 | 226.75 Mn |
| Jun 30, 2022 | 224.81 Mn |
| Mar 31, 2022 | 218.42 Mn |
| Dec 31, 2021 | 216.28 Mn |
| Sep 30, 2021 | 158.59 Mn |
| Jun 30, 2021 | 153.80 Mn |